Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$5.91 USD
+0.30 (5.35%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Corvus Pharmaceuticals, Inc. [CRVS]
Reports for Purchase
Showing records 61 - 80 ( 154 total )
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CPI-006 Catalysts Could Unlock Value; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Expanding CPI-006 Utility Beyond Cancer to Treat COVID-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Corvus Begins an Immunotherapy Trial to Fight COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CPI-006 Enters COVID-19 Study; Increasing PT to $8
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CD68 Positivity Could be a Superior Biomarker to AdenoSig; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Defining a Patient Population Where Adenosine Therapy May Have High Utility
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CORRECTED: ASCO Virtual Meeting Abstract Roundup
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare-Check Out Our Highlights From 2020 ASCO Abstracts
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Three Clinical Updates at Three Major Medical Meetings in 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q20: A Plan to Advance Adenosine- Blocking Therapy into the Clinic
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Register for Our Webinar: ACSO Abstract Titles Review '-' April 30th at 10am ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T